Skip to main content

Sanofi

corporate_fare Company Profile

Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health – Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed SNY - Latest Insights

SNY
Apr 29, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
7
SNY
Apr 27, 2026, 12:58 PM EDT
Filing Type: 6-K
Importance Score:
8
SNY
Apr 24, 2026, 6:09 AM EDT
Source: GlobeNewswire
Importance Score:
8
SNY
Apr 23, 2026, 7:20 AM EDT
Filing Type: 6-K
Importance Score:
8
SNY
Apr 18, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
SNY
Apr 15, 2026, 6:57 AM EDT
Filing Type: 6-K
Importance Score:
8
SNY
Apr 07, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
SNY
Mar 31, 2026, 12:19 PM EDT
Filing Type: 6-K
Importance Score:
7
SNY
Mar 31, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
SNY
Mar 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
SNY
Mar 18, 2026, 2:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
SNY
Mar 03, 2026, 6:15 AM EST
Filing Type: 6-K
Importance Score:
8
SNY
Feb 23, 2026, 9:19 AM EST
Filing Type: 6-K
Importance Score:
8
SNY
Feb 17, 2026, 12:34 PM EST
Filing Type: 20-F
Importance Score:
8
SNY
Feb 17, 2026, 9:33 AM EST
Filing Type: 6-K
Importance Score:
8
SNY
Feb 12, 2026, 9:17 AM EST
Filing Type: 6-K
Importance Score:
8
SNY
Feb 10, 2026, 9:18 AM EST
Filing Type: 6-K
Importance Score:
8
SNY
Feb 10, 2026, 6:06 AM EST
Filing Type: SC TO-T/A
Importance Score:
9
SNY
Feb 06, 2026, 10:09 AM EST
Filing Type: 6-K
Importance Score:
8
SNY
Jan 30, 2026, 7:55 AM EST
Filing Type: SC TO-T/A
Importance Score:
8